CAVA: Dizziness Trial (CAVA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04026516|
Recruitment Status : Recruiting
First Posted : July 19, 2019
Last Update Posted : October 8, 2020
|Condition or disease||Intervention/treatment||Phase|
|Meniere's Disease Benign Paroxysmal Positional Vertigo Recurrent Vestibulopathy Vestibular Migraine||Device: CAVA Device||Not Applicable|
Dizziness is a common condition that is responsible for a significant degree of material morbidity and burden on our health service. There are multiple causes of dizziness, and these originate from pathologies affecting a large variety of different organ systems. Dizziness is usually episodic and short-lived, so when a patient presents to their health care provider, examination is often normal. As such, diagnosis is challenging and patients often experience significant delay in receiving a diagnosis.
The investigators have developed a prototype device for monitoring dizziness and have tested it in a group of 17 healthy volunteers. The results showed that their device is capable of accurately, precisely and reliably identifying short periods of induced nystagmus (eye movements produced during dizzy attacks) among days' worth of normal eye movement data.
The overall aim of this trial is to test a fully evolved device for the continuous recording of eye movements over a prolonged period of time, on patients suffering from dizziness. For the purpose of this study, the monitoring period is 23 hours a day, for 30 days. The device is composed of two components: a bespoke single-use sensor array that adheres to the participant's face, and a small reusable module that contains a battery, microcomputer, data storage facility, battery and connection port.
The investigators intend to confirm that the device data can be used to identify any occurrence of nystagmus, as produced during attacks of vertigo. Each trial participant will be provided with the device and enough single-use electrode arrays to allow the array to be changed every 24 hours, for thirty days. Participants will be allowed to remove the sensor array for up to 60 minutes each day to allow them to wash and/or shower. If patients experience an episode of dizziness during the trial, they are required to log the details of the event in a trial diary. The identity of these days will not be revealed to the blinded investigator who will later conduct a formal, blinded analysis of the data. At the end of the thirty-day trial, the sensitivity and specificity of the device will be determined by assessing whether the data can be used to correctly identify the dates that participants reported dizziness.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Production of a Device to Obtain Continuous Ambulatory Vestibular Assessment (CAVA) - Dizziness Trial|
|Actual Study Start Date :||July 1, 2019|
|Estimated Primary Completion Date :||June 30, 2021|
|Estimated Study Completion Date :||October 31, 2021|
Experimental: CAVA Dizziness Trial Arm
All trial participants are within this arm. All participants will wear the CAVA device for 30 days and follow the same procedures throughout the trial.
Device: CAVA Device
The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
- Nystagmus detection sensitivity and specificity of 95% [ Time Frame: 30 days ]The investigators will determine the sensitivity and specificity of the results obtained by a bespoke computer algorithm for detecting episodes of nystagmus, from data captured by the CAVA device.
- Post-trial participant questionnaire [ Time Frame: 30 days ]A questionnaire will be provided to the participants at the end of the trial to gather data on device acceptability and other patient feedback. A qualitative assessment of this data will be performed. The device acceptability is measured over 8 questions regarding comfort of wear, ease of wear, self consciousness, effect on sleep with each question having a scale of 1-5. With 5 being the best outcome and 1 being the worst outcome.
- Compliance with wearing the device [ Time Frame: 30 days ]Investigators will check the participants compliance of wearing the device by using the data in the participants' trial diaries.
- Functionality of the device's accelerometer [ Time Frame: 30 days ]Data will be downloaded from the device and manually checked to ensure that valid data has been captured.
- Functionality of the device's event marker [ Time Frame: 30 days ]Data will be downloaded from the device and manually checked to ensure that the known dates and times of event marker activation match the record stored on the device.
- Functionality of the device's timestamping capabilities [ Time Frame: 30 days ]The known dates and times of event marker activations will be compared to the record stored on the device. From this information, clock drift will be calculated (hh:mm:ss).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04026516
|Contact: John Phillips, Consultant||+44 1603 firstname.lastname@example.org|
|Contact: Jacob Newman, Dr||+44 1603 email@example.com|
|Norfolk & Norwich University Hospitals NHS Foundation Trust||Recruiting|
|Norwich, Norfolk, United Kingdom, NR4 7UY|
|Contact: Julie Dawson, Mrs +44 1603 286611 firstname.lastname@example.org|
|Principal Investigator:||John Phillips, Consultant||Dr|